Shenzhen Haibin Pharmaceutical Co., Ltd.

This study aims to evaluate the pharmacokinetic characteristics of JKN2306 tablets in participants with mild to moderate hepatic impairment and to compare them with those in participants with normal hepatic function, providing a scientific basis for rational clinical use of the drug in participants with hepatic impairment.

To evaluate the effect of multiple oral administrations of JKN2306 tablets on the pharmacokinetic characteristics of a single oral administration of the OATP1B1 substrate pravastatin. To evaluate the effect of multiple oral administrations of JKN2306 tablets on the pharmacokinetic characteristics of a single oral administration of the CYP2B6 substrate bupropion. To evaluate the effect of multiple oral administrations of JKN2306 tablets on the pharmacokinetic characteristics of hydroxybupropion, the major active metabolite produced after a single oral administration of bupropion.

Part I: Study Objectives Primary Objective: To evaluate the safety and tolerability of JKN2502 administered intravenously in healthy participants in the Chinese trial. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of JKN2502 administered intravenously in healthy participants in the Chinese trial; 2) To evaluate the effect of plasma drug concentration on the QT/QTc interval after intravenous administration of JKN2502 in healthy participants in the Chinese trial. Exploratory Objective: To preliminarily analyze the metabolites of JKN2502 in plasma, urine, and feces. Part II: Study Objectives Primary Objective: To evaluate the pharmacokinetic characteristics of a single intravenous infusion of JKN2502 in participants with normal renal function and varying degrees of renal impairment. Secondary Objective: To evaluate the safety and tolerability of intravenous infusion of JKN2502 in participants with normal renal function and mild, moderate, and severe renal impairment. Exploratory Objective: To explore the correlation between pharmacokinetic parameters of JKN2502 and renal function indicators (such as eGFR, serum creatinine, etc.).